Log In Sign Up

A bayesian reanalysis of the phase III aducanumab (ADU) trial

by   Tommaso Costa, et al.

In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the evidence on the efficacy of the drug is very low and a more clearer view of the results of clinical trials are presented in the Bayesian framework that can be useful for future development and research in the field.


page 4

page 5

page 7


Improving the assessment of the probability of success in late stage drug development

There are several steps to confirming the safety and efficacy of a new m...

Bayesian Persuasion in Sequential Trials

We consider a Bayesian persuasion or information design problem where th...

Phases of methodological research in biostatistics - building the evidence base for new methods

Although the biostatistical scientific literature publishes new methods ...

Adversity Index for Clinical Trials: An Inclusive Approach for Analysis of Safety Data

This paper proposes a new method for analysis of adverse event data in c...

Towards More Flexible False Positive Control in Phase III Randomized Clinical Trials

Phase III randomized clinical trials play a monumentally critical role i...

Towards reliable and transparent vaccine phase III trials with smart contracts

Transforming a vaccine concept into a real vaccine product is a complica...

Predicting Clinical Trial Results by Implicit Evidence Integration

Clinical trials provide essential guidance for practicing Evidence-Based...